April 2nd 2021
Jason Porter, MD, Subramanian Janakiraman, MD, Natalie S. Calendar, MD, Parameswaran Hari, MD, MRCP, and Kevin Kalinsky, MD, MS, discuss the importance of the Institutional Perspectives in Cancer webinars.
March 9th 2021
Parameswaran Hari, MD, MRCP, shares key considerations for the treatment of patients with relapsed/refractory multiple myeloma.
February 17th 2021
Parameswaran Hari, MD, MRCP, discusses the efficacy of combination carfilzomib, pomalidomide, and dexamethasone in patients with relapsed/refractory multiple myeloma.
February 16th 2021
Parameswaran Hari, MD, MRCP, discusses mitigating selinexor-related toxicities in relapsed/refractory multiple myeloma.
January 19th 2021
Parameswaran Hari, MD, MRCP, discusses treatment strategies for patients with relapsed/refractory multiple myeloma.
June 16th 2020
Parameswaran Hari, MD, MRCP, discusses the current and potential future utility of ixazomib (Ninlaro) maintenance in multiple myeloma.
June 12th 2020
Parameswaran Hari, MD, MRCP, discusses the role of minimal residual disease in multiple myeloma.
March 19th 2020
Parameswaran Hari, MD, MRCP, discusses misconceptions regarding allogeneic stem cell transplant in multiple myeloma.
January 30th 2020
Parameswaran Hari, MD, MRCP, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.
May 23rd 2019
Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the current state of frontline therapy in multiple myeloma.
May 8th 2019
Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the role of minimal residual disease in myeloma.